GB2276624A - Inactivation of cytotoxic drugs - Google Patents

Inactivation of cytotoxic drugs

Info

Publication number
GB2276624A
GB2276624A GB9410237A GB9410237A GB2276624A GB 2276624 A GB2276624 A GB 2276624A GB 9410237 A GB9410237 A GB 9410237A GB 9410237 A GB9410237 A GB 9410237A GB 2276624 A GB2276624 A GB 2276624A
Authority
GB
United Kingdom
Prior art keywords
drug
cytotoxic
component
portion capable
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9410237A
Other versions
GB2276624B (en
GB9410237D0 (en
Inventor
Kenneth Dawson Bagshawe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB9410237A priority Critical patent/GB2276624B/en
Publication of GB9410237D0 publication Critical patent/GB9410237D0/en
Publication of GB2276624A publication Critical patent/GB2276624A/en
Application granted granted Critical
Publication of GB2276624B publication Critical patent/GB2276624B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A three component kit of parts for use in a method of destroying target cells in a host is provided. The first component comprises a target cell-specific portion and an enzymatically active portion capable of converting a cytotoxic pro-drug into a cytotoxic drug. The second component is a cytotoxic pro-drug convertible by said enzymatically active portion to the cytotoxic drug. The third component comprises a portion capable of at least partly restraining the component from leaving the vascular compartment of a host when said compound is administered to the vascular compartment, and an inactivating portion capable of converting the cytotoxic drug into a less toxic substance.
GB9410237A 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host Expired - Fee Related GB2276624B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9410237A GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929200415A GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs
PCT/GB1993/000040 WO1993013806A1 (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs
GB9410237A GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host

Publications (3)

Publication Number Publication Date
GB9410237D0 GB9410237D0 (en) 1994-07-27
GB2276624A true GB2276624A (en) 1994-10-05
GB2276624B GB2276624B (en) 1995-10-25

Family

ID=26300132

Family Applications (3)

Application Number Title Priority Date Filing Date
GB929200415A Pending GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A Pending GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs
GB9410237A Expired - Fee Related GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host

Family Applications Before (2)

Application Number Title Priority Date Filing Date
GB929200415A Pending GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A Pending GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs

Country Status (5)

Country Link
EP (1) EP0620742A1 (en)
JP (1) JPH07506339A (en)
CA (1) CA2124217A1 (en)
GB (3) GB9200415D0 (en)
WO (1) WO1993013806A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
WO1999061406A2 (en) * 1998-05-22 1999-12-02 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
CO5170498A1 (en) * 1999-05-28 2002-06-27 Abbott Lab BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS
FR2883873B1 (en) * 2005-03-31 2009-07-10 Pharmamens Sarl AGE INHIBITORS
US7732309B2 (en) * 2006-12-08 2010-06-08 Applied Materials, Inc. Plasma immersed ion implantation process
EP2603528B1 (en) * 2010-08-10 2016-10-12 Glycotope GmbH Fab-glycosylated antibodies
EP3794041B1 (en) 2018-05-18 2023-07-12 Glycotope GmbH Anti-muc1 antibody

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (en) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Improvements relating to drug delivery systems
EP0308208A1 (en) * 1987-09-14 1989-03-22 Center For Molecular Medicine And Immunology Modified antibody conjugates with enhanced clearance
WO1989010140A1 (en) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Further improvements relating to drug delivery systems
WO1990009134A1 (en) * 1989-02-13 1990-08-23 Cosgrove James H Device for releasably supporting a plurality of objects
WO1990010460A1 (en) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Method for reducing side effects of a drug
EP0506124A1 (en) * 1991-03-27 1992-09-30 Tanox Biosystems, Inc. Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505566A1 (en) * 1989-12-15 1992-09-30 Takeda Chemical Industries, Ltd. Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (en) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Improvements relating to drug delivery systems
EP0308208A1 (en) * 1987-09-14 1989-03-22 Center For Molecular Medicine And Immunology Modified antibody conjugates with enhanced clearance
WO1989010140A1 (en) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Further improvements relating to drug delivery systems
WO1990009134A1 (en) * 1989-02-13 1990-08-23 Cosgrove James H Device for releasably supporting a plurality of objects
WO1990010460A1 (en) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Method for reducing side effects of a drug
EP0506124A1 (en) * 1991-03-27 1992-09-30 Tanox Biosystems, Inc. Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antibody,Immunoconjugates,Radiopharm. 1988,1(2),169-180 *
Proc.Natl.Acad.Sci.USA 1983,80,3078-3080 *

Also Published As

Publication number Publication date
CA2124217A1 (en) 1993-07-22
GB9204104D0 (en) 1992-04-08
WO1993013806A1 (en) 1993-07-22
EP0620742A1 (en) 1994-10-26
GB9200415D0 (en) 1992-02-26
GB2276624B (en) 1995-10-25
JPH07506339A (en) 1995-07-13
GB9410237D0 (en) 1994-07-27

Similar Documents

Publication Publication Date Title
GB2276623A (en) Cytotoxic drug therapy
EP0276317A4 (en) Gamma-l-glutamyl-l-cysteine ethyl ester and drug containing it as effective ingredient.
YU48099A (en) Composition that involves nutrient and herb and its application
AU562803B2 (en) Oral antidiabetic composition
DK1393750T3 (en) Antibodies to treat an immune disease
GB2276624A (en) Inactivation of cytotoxic drugs
DE69434121D1 (en) PHARMACEUTICAL COMPOSITION FOR IMMUNITIMULATING THERAPY
AU7535494A (en) Pharmaceutical preparations for the targeted treatment of morbus crohn and colitis ulcerosa
CA2208047A1 (en) Increasing creatine and glycogen concentration in muscle
AU5195593A (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
AU2084801A (en) Antiviral medication
PT78628B (en) Pharmaceutical composition with reduced toxicity
AU4445089A (en) Lactamimides in the treatment of drug-resistant protozoal infections
MY104937A (en) Cephalosporin derivatives and processes for their preparation
GR3008170T3 (en)
AU1518492A (en) Pharmaceutical compositions for transcutaneous administration
AU3445489A (en) Luminide and macroluminide class of pharmaceuticals
JO1866B1 (en) Anti-viral agents
AU5060090A (en) Pharmaceutical treatment
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
DE59205998D1 (en) Medicament with antineoplastic activity containing octadecyl- [2- (N-methylpiperidino) ethyl] phosphate as active ingredient and process for its preparation
CS346691A3 (en) Complexes containing s-(+)-phenylalkanoic acids and alpha-hydroxyalkanoic acids
AU7511694A (en) Inclusion complexes of racemic ibuproxam and of optically active ibuproxam with cyclodextrin derivatives, process for the preparation thereof, pharmaceutical preparations containing these inclusion complexes or containing optically active s-(+)-ibuproxam, and use thereof
AU633196B2 (en) Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease
AU4807990A (en) Antinephrotoxic perfusion solution

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20010111